Hong Kong is expanding clinical trials of histotripsy, a non-invasive tumor treatment. The CUHK Medical Center, Gleneagles Hospital Hong Kong, and Hong Kong Sanatorium & Hospital will conduct trials targeting 30 kidney cancer patients. The Li Ka Shing Foundation stated that this initiative aims to make Hong Kong the first city in Asia to verify the safety and efficacy of this technology in treating kidney diseases.